Insider Profile
Davert, Marshall
1
Companies Filed At
0
Open-Market Buys (2yr)
—
Buy Value (2yr, open-market)
Jun 21, 2024
Most Recent Trade
63
Credibility
Score
80%
Hit Rate
+9.6%
Avg 90d Return
+5.9%
Median 90d Return
30
Evaluated Trades
+30.7%
Best Trade
-11.5%
Worst Trade
Hit rate and returns are based on 30 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. This insider has a solid track record of profitable timing.
Cross-Company Track Record
100%
Hit Rate · 90d
-5.7%
Median Alpha · 90d
4
Closed Buys Evaluated
0%
Beat XIU
All-insider base rate: 59% hit rate  · +1.3% mean alpha (n=11504)
cluster buyer size concentrated
Entry: closing price on SEDI filing date (point-in-time). Exit: 90 calendar days later. Alpha vs XIU.TO (iShares TSX 60). Closed trades only. Not investment advice.
Research 4 closed buys with individual return outcomes available on the Research plan.
Date Company Role Nature Dir. Shares Price Value Score
Jun 21, 2024 $STN
Stantec
— Other Sell 854 $115.10 $98K 63
Jun 21, 2024 $STN
Stantec
— Other Sell 3,413 $174.15 $594K 63
Dec 31, 2023 $STN
Stantec
— Plan / DRIP Buy 84 $88.80 $7K 63
Dec 31, 2023 $STN
Stantec
— Plan / DRIP Buy 21 $88.81 $2K 63
Jul 03, 2023 $STN
Stantec
— Open Market Buy 11,000 $64.62 $711K 63
Jun 23, 2023 $STN
Stantec
— Other Sell 4,810 $101.22 $487K 63
Jun 23, 2023 $STN
Stantec
— Other Sell 1,202 $82.16 $99K 63
May 15, 2023 $STN
Stantec
— Comp. Grant Buy 466 $80.64 $38K 63
May 15, 2023 $STN
Stantec
— Comp. Grant Buy 1,861 $80.64 $150K 63
Dec 31, 2022 $STN
Stantec
— Plan / DRIP Buy 140 $62.77 $9K 63
Dec 31, 2022 $STN
Stantec
— Plan / DRIP Buy 35 $62.77 $2K 63
Dec 31, 2022 $STN
Stantec
— Plan / DRIP Buy 1,264 $45.62 $58K 63
Jun 24, 2022 $STN
Stantec
— Other Sell 1,448 $55.38 $80K 63
Jun 24, 2022 $STN
Stantec
— Other Sell 5,794 $49.07 $284K 63
May 16, 2022 $STN
Stantec
— Comp. Grant Buy 890 $54.50 $49K 63
May 16, 2022 $STN
Stantec
— Comp. Grant Buy 3,558 $54.50 $194K 63
Dec 31, 2021 $STN
Stantec
— Plan / DRIP Buy 35 $60.75 $2K 63
Dec 31, 2021 $STN
Stantec
— Plan / DRIP Buy 372 $45.16 $17K 63
Dec 31, 2021 $STN
Stantec
— Plan / DRIP Buy 69 $47.07 $3K 63
Dec 31, 2021 $STN
Stantec
— Comp. Grant Buy 3,312 $53.45 $177K 63
Dec 31, 2021 $STN
Stantec
— Comp. Grant Buy 829 $53.45 $44K 63
Dec 31, 2021 $STN
Stantec
— Plan / DRIP Buy 140 $60.75 $9K 63
Jun 25, 2021 $STN
Stantec
— Exercise Buy 4,034 $32.98 $133K 63
Jun 25, 2021 $STN
Stantec
— Exercise Sell 4,034 $32.98 $224K 63
Apr 30, 2021 $STN
Stantec
— Ownership Chg Sell 9,344 — — 63
Apr 30, 2021 $STN
Stantec
— Ownership Chg Buy 9,344 — — 63
Apr 23, 2021 $STN
Stantec
— Other Sell 4,399 $38.58 $170K 63
Mar 23, 2021 $STN
Stantec
— Exercise Buy 14,243 $31.75 $452K 63
Mar 23, 2021 $STN
Stantec
— Exercise Sell 8,064 $32.98 $266K 63
Mar 23, 2021 $STN
Stantec
— Exercise Sell 14,243 $31.75 $452K 63
Mar 23, 2021 $STN
Stantec
— Open Market Buy 8,064 $53.50 $431K 63
Mar 23, 2021 $STN
Stantec
— Exercise Buy 8,064 $32.98 $266K 63
Mar 23, 2021 $STN
Stantec
— Open Market Buy 14,243 $53.50 $762K 63
Dec 31, 2020 $STN
Stantec
— Comp. Grant Buy 1,160 $42.00 $49K 63
Dec 31, 2020 $STN
Stantec
— Plan / DRIP Buy 3,137 $28.87 $91K 63
Dec 31, 2020 $STN
Stantec
— Plan / DRIP Buy 74 $32.17 $2K 63
Dec 31, 2020 $STN
Stantec
— Plan / DRIP Buy 201 $41.72 $8K 63
Dec 31, 2020 $STN
Stantec
— Plan / DRIP Buy 34 $41.79 $1K 63
Dec 31, 2020 $STN
Stantec
— Comp. Grant Buy 4,641 $42.00 $195K 63
May 11, 2020 $STN
Stantec
— Exercise Buy 12,959 $32.83 $425K 63
May 11, 2020 $STN
Stantec
— Open Market Buy 12,959 $42.00 $544K 63
May 11, 2020 $STN
Stantec
— Exercise Sell 12,959 $32.83 $425K 63
Apr 24, 2020 $STN
Stantec
— Other Sell 4,725 $39.84 $188K 63
Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Confluence Scores reflect the company's current score, not the score at time of trade.
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.